Henter, Ioline D. http://orcid.org/0000-0002-2379-2413
Park, Lawrence T. http://orcid.org/0000-0002-6570-686X
Zarate, Carlos A. Jr. http://orcid.org/0000-0003-4442-7412
Funding for this research was provided by:
National Institute of Mental Health (ZIAMH002857)
Article History
Accepted: 3 April 2021
First Online: 26 April 2021
Declarations
:
: Funding for this work was provided by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH; ZIAMH002857). The work was completed as part of the authors’ official duties as Government employees. The views expressed do not necessarily reflect the views of the NIH, the Department of Health and Human Services, or the United States Government.
: Dr Zarate is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine, (<i>S</i>)-dehydronorketamine, and other stereoisomeric dehydro and hydroxylated metabolites of (<i>R,S</i>)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2<i>R</i>,6<i>R</i>)-hydroxynorketamine and (2<i>S</i>,6<i>S</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the US government but will share a percentage of any royalties that may be received by the government. All other authors have no conflict of interest to disclose, financial or otherwise.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors contributed equally to the literature search, generation of the table and figure, writing, and revision of this manuscript. All authors approved the final version of the paper.